Vivos: The Boston Cancer Treatment Licensing Proposal With a Mysterious Final Clause
James Anderson | Boston Bureau
Boston. 9:35 PM. A cancer treatment technology licensing proposal enters its final review. Research milestones and future royalty payments dominate the discussions.
One unexpected contract clause threatens to derail the agreement. Watch for the next chapter.
Continue Your Research
Browse the Stock Ratings Directory
Explore Buyout Watch
Visit the Trading Academy
Browse Biotech Catalyst Watch
Browse OTC Buzz Tracker